🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareAdolescent obesity: AAP guidelines and GLP-1 use in minors Page 5

Adolescent obesity: AAP guidelines and GLP-1 use in minors

PedsEndoPhilly Mon, Feb 23, 2026 at 8:38 AM 22 replies 811 viewsPage 5 of 5
GraceAZ_72
Member
156
678
Jan 2025
Tucson, AZ
Feb 23, 2026 at 3:43 PM#21

ricardo_MIA — that is really helpful context on Adolescent obesity AAP. Follow-up question: what labs did your doctor order to monitor this?

I am in a similar situation (just started) and trying to set realistic expectations.

31 21MariaRD, AussieAnna, BethLabQueen and 28 others
Reply Quote Save Share Report
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Feb 23, 2026 at 4:00 PM#22

To answer LondonLisa's question specifically:

From a clinical standpoint, Adolescent obesity AAP is an area where we have good evidence.

The short answer: baseline labs + quarterly monitoring is the standard of care.

The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.

48 9traveltech_sara, AttorneyGrant, DebRD_ATL and 45 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Feb 23, 2026 at 4:17 PM#23

Thank you GraceAZ_72! This is incredibly helpful. Bookmarking for later. 🙏

16 18MikeNYC_runner and 13 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Feb 23, 2026 at 4:34 PM#24

Relevant to Adolescent obesity AAP — here is my latest bloodwork comparison:

Key improvements: A1C 8.4% → 5.5%, triglycerides 213 → 113 mg/dL, hsCRP 8.0 → 1.3 mg/L. All on tirzepatide for 17 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

49 2sophie_paris, mel_PDX, Dr.AddMedPHL and 46 others
Reply Quote Save Share Report
sean_dublin
Member
212
890
Nov 2024
Dublin, IE
Feb 23, 2026 at 4:51 PM#25

Slightly tangential to Adolescent obesity AAP but GraceAZ_72 reminded me — what is the latest on the oral formulations?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Last edited: Feb 23, 2026 at 5:51 PM
29 0quinn_sf, NurseLeah_Nash, gary_naperville and 26 others
Reply Quote Save Share Report
1345

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register